Atherosclerosis Treatment Drugs Market with Major Provincial
Sectors, key players such as GlaxoSmithKline plc. Merck & Co.,
Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc.
Atherosclerosis is characterized by the narrowing and hardening of the arteries. In this
condition, arteries become blocked by fatty substances, such as cholesterol. These substances are
called as plaques or atheroma. The risks of atherosclerosis increase with age. The deposition of
plaque tends to narrow the arterial canal, which result in the limited flow of blood and oxygen
through it. Atherosclerosis commences with damage to the endothelium of arteries leading to
the formation of plaque. This condition is dangerous for the vital organs such as heart and
brain. The risk associated with atherosclerosis includes serious cardiovascular and brain diseases.
Collectively, these conditions are more common for cardiovascular diseases (CVD) including
coronary heart disease, angina pectoris, and transitory ischemia. Other risks for atherosclerosis
are carotid artery disease, kidney disease, and peripheral artery disease.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2430
Atherosclerosis Treatment Drugs Market – Driver
Increasing number of pipeline studies and rising involvement of key players for developing the
treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs
market growth. For Instance, in November 13, 2018, Bayer in collaboration with Janssen, LP
started the clinical study for Rivaroxaban and Acetylsalicylic Acid to build up the insights in
treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with
acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to
complete in August 2021.